Extended Data Fig. 2. Participant-level changes in liver fat.
Data for all participants is shown, excluding data after discontinuation of treatment. One of the participants in the 8 mg dose group missed the last two doses of retatrutide, despite being marked as treatment completed by the investigator. This may have contributed to the lesser relative liver fat reduction at week 48 (−68.5%) compared with week 24 (−84.5%) for this participant.